You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥AH股齊升 子公司藥品獲批臨牀試驗
格隆匯8月10日丨復星醫藥(2196.HK)現報67.85港元,漲4.71%,暫成交1億港元,最新市值1739億港元;復星醫藥(600196.SH)現亦漲超3%,報79元。復星醫藥昨日晚間發公吿稱,近日,公司控股子公司復星醫藥產業收到國家藥品監督管理局關於同意其參與研製的FH-2001膠囊用於晚期惡性實體瘤開展臨牀試驗的批准。復星醫藥產業擬於條件具備後於中國大陸開展該新藥的I期臨牀試驗。該新藥為PD-L1/FGFR雙機制小分子調節/抑制劑,擬主要用於治療晚期實體瘤;該新藥臨牀前研究主要由上海藥明康德新藥開發有限公司受託開展、臨牀研究及後續商業化擬由集團(即公司及控股子公司/單位)自主實施。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.